¹³¹I联合甲巯咪唑治疗Graves病的效果及对机体免疫的影响研究

蔡丽娟 任妹 刘剑荣 潘幸

【摘要】 目的：探究与观察131I联合甲巯咪唑治疗Graves病的效果及对机体免疫的影响。方法：选取2016年7月-2018年12月120例Graves病患者为研究对象，将其根据随机数字表法分为对照组和观察组，每组60例。对照组采用甲巯咪唑治疗，观察组采用131I联合甲巯咪唑治疗。比较两组的临床总有效率、治疗前后的甲状腺激素、疾病相关抗体及外周血T淋巴细胞亚群指标。结果：治疗6個月后，观察组的临床总有效率高于对照组，差异有统计学意义（P<0.05）。治疗前，两组的甲状腺激素、疾病相关抗体及外周血T淋巴细胞亚群指标比较，差异均无统计学意义（P>0.05）;治疗3、6个月后，观察组的血清TSH及CD3+、CD4+/CD8+均高于对照组，其他甲状腺激素、疾病相关抗体及CD8+均低于对照组，差异均有统计学意义（P<0.05）。结论：131I联合甲巯咪唑在Graves病患者中的应用效果较好，且对机体免疫的影响相对更大，因此在Graves病患者中的应用价值相对较高。

【关键词】 131I 甲巯咪唑 Graves病 机体免疫

[Abstract] Objective： To study and observe the effect of 131I combined with Methimazole in the patients with Graves disease and influence for body immune. Method： A total of 120 patients with Graves disease from July 2016 to December 2018 were selected the study and divided into control group and observation group according to random number table method， with 60 cases in each group. Methimazole was administered to the control group， the observation group received 131I combined with Methimazole. Then the total effective rates， thyroid hormones， disease-related antibody and peripheral blood T lymphocyte subsets indexes before and after the treatment of two groups were compared. Result： After 6 months of treatment， the total effective rate of observation group was higher than that of control group， there was statistically significant difference （P<0.05）. The thyroid hormones， disease-related antibody and peripheral blood T lymphocyte subsets indexes of two groups before the treatment were compared， there were no statistically significant differences （P>0.05）; after 3 and 6 months of treatment， serum TSH and CD3+， CD4+/CD8+ of observation group were higher than those in the control group， while other thyroid hormones， disease-related antibodies and CD8+ were lower than those in the control group， there were statistically significant differences （P<0.05）. Conclusion： The application effect of 131I combined with Methimazole in the patients with Graves disease is better， and its influence of the body immune are greater， so its application value in the patients with Graves disease is relatively higher.

[Key words] 131I Methimazole Graves disease Body immune

First-author’s address： Pingxiang People’s Hospital， Pingxiang 337000， China

doi：10.3969/j.issn.1674-4985.2021.17.043

Graves病在临床并不乏见，而本病可对多系统器官造成不良影响，临床治疗需求较高，重视程度也较高，而与之相关的各方面研究多见，其中机体免疫是在本类患者中表现突出的方面[1-2]，而外周血T淋巴细胞亚群作为细胞免疫的常见检测方面，其在Graves病患者中的表达显著异常，是有效评估且亟待改善的方面，同时也是疾病控制措施可取性的重要参考方面。临床中采用131I联合甲巯咪唑治疗在Graves病的研究中可见，但是其对患者的效果研究差异普遍存在[3-5]，且对机体免疫的细致影响研究不足。……